Díaz-Redondo, T., Lavado-Valenzuela, R., Jimenez, B., Pascual, T., Gálvez, F., Falcón, A., . . . Alba, E. (2019). Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. Front Oncol.
Trích dẫn kiểu ChicagoDíaz-Redondo, Tamara, et al. "Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab Vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data." Front Oncol 2019.
Trích dẫn MLADíaz-Redondo, Tamara, et al. "Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab Vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data." Front Oncol 2019.